Loading…
Life-Threatening Diseases Compassion through Combination Therapy Act of 2012
Legislative Progress
Introduced
September 21, 2012
Latest Action
September 26, 2012
Primary Sponsor
Brian P. BilbrayRepublican(CA)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
29pct
5d open
vs 6,662 other HR bills in the 112th — cohort avg 39d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2012 · third_quarter · Copyright/Patent/Trademark
HR 2182, S1734, and S2187 (as passed in Pub. L. No. 112-144) issues related to the development of antibiotics H.R. 6353 - issues related to providing intelletual property incentives for manufacturing H.R. 6502 - issues related to the provision on incentives for development of medicines for life-threatening illnesses
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $900,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2012 · third_quarter · Health Issues
HR 2182, S1734, and S2187 (as passed in Pub. L. No. 112-144) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumerHR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to 340B program amendments and implementation of statutory changes. HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to definition of essential health benefits and health insurance exchanges. HR 6160 - issues related to drug safety issues, including tamper resistent packaging HR 1513 - issues related to animal research HR 6502 - issues related to development of medicines for life-threatening illnesses HR 3497 - issues related to incentives for developing and improving diagnostic tests and related treatments HR 6272 - issues related to the expansion of clinical trial data banks and increase government reporting of same HR 6163 - issues related to incentives for increased research into pediatric treatments
Client expense: $900,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2012 · fourth_quarter · Copyright/Patent/Trademark
H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: Provisions related to authorized generics H.R. 3261, Stop Online Piracy Act: Provisions related to anti-counterfeiting H.R. 3468, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti-counterfeiting H.R. 3995, Protect Consumer Access to Generic Drugs Act: Provisions related to patent settlements H.R. 4216, Foreign Counterfeit Protection Act: Provisions related to anti-counterfeiting H.R. 6502, Life-Threatening Diseases Compassion through Combination Therapy Act: Provisions related to market exclusivity and expedited review H.R. 6621, a bill to make technical corrections to the America Invents Act H.R. 6654, Foreign Counterfeit Merchandise Prevention Act: Provisions related to trade enforcement S. 27, The Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 373, The Fair Prescription Drug Competition Act: Provisions related to authorized generics S. 968, Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011: Provisions related to anti-counterfeiting S. 1734, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives S. 1882, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 1886, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti- counterfeiting S. 3486, Patent Law Treaties Implementation Act of 2012: Patent law treaties S. 3652, Patents for Humanity Program Improvements Act of 2012: Provisions related to transferability of PTO acceleration certificates International intellectual property issues Biopharmaceutical innovation policy issues
Client expense: $4,120,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
2012 · fourth_quarter · Health Issues
H.R.1676, Tanning Bed Cancer Control Act of 2011, Issues pertaining to the regulation of tanning beds. Public Law 111-148, Patient Protection and Affordable Care Act, Tax on tanning beds. Public Law 111-152, Health Care and Education Reconciliation Act of 2010, Tax on tanning beds. Public Law 112-144, Food & Drug Administration Safety and Innovation Act, Regulation on tanning beds. H.R.6502, To amend title V of the Federal Food, Drug, and Cosmetic Act to provide for extensions of marketing exclusivity periods for drugs in certain combinations of such drugs, and for other purposes, Tanning bed issues.
Client expense: Not reported · Firm income: $20,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2012 · fourth_quarter · Medicare/Medicaid
S. 4040/H.R. 6502, The Medicare Beneficiary Preservation of Choice Act of 2012; Medigap; Medicare Advantage; Medicaid; and Dual Eligible Coverage.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Health Issues
HR 2182, S1734, and S2187 (as passed in Pub. L. No. 112-144) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to 340B program amendments and implementation of statutory changes. HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to definition of essential health benefits and health insurance exchanges. HR 6160 - issues related to drug safety issues, including tamper resistent packaging HR 1513 - issues related to animal research HR 6502 - issues related to development of medicines for life-threatening illnesses HR 3497 - issues related to incentives for developing and improving diagnostic tests and related treatments HR 6272 - issues related to the expansion of clinical trial data banks and increase government reporting of same HR 6163 - issues related to incentives for increased research into pediatric treatments
Client expense: $980,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2012 · third_quarter · Copyright/Patent/Trademark
HR 2182, S1734, and S2187 (as passed in Pub. L. No. 112-144) issues related to the development of antibiotics H.R. 6353 - issues related to providing intelletual property incentives for manufacturing H.R. 6502 - issues related to the provision on incentives for development of medicines for life-threatening illnesses
Client expense: $980,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2012 · third_quarter · Medicare/Medicaid
S. 4040/H.R. 6502, The Medicare Beneficiary Preservation of Choice Act of 2012; Medigap; Medicare Advantage; Medicaid; and Dual Eligible Coverage.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2012 · third_quarter · Health Issues
H.R.1676, Tanning Bed Cancer Control Act of 2011, Issues pertaining to the regulation of tanning beds. Public Law 111-148, Patient Protection and Affordable Care Act, Tax on tanning beds. Public Law 111-152, Health Care and Education Reconciliation Act of 2010, Tax on tanning beds. Public Law 112-144, Food & Drug Administration Safety and Innovation Act, Regulation on tanning beds. H.R.6502, To amend title V of the Federal Food, Drug, and Cosmetic Act to provide for extensions of marketing exclusivity periods for drugs in certain combinations of such drugs, and for other purposes, Tanning bed issues.
Client expense: Not reported · Firm income: $10,000
Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2012 · second_quarter · Medicare/Medicaid
S. 4040/H.R. 6502, The Medicare Beneficiary Preservation of Choice Act of 2012; Medigap; Medicare Advantage; Medicaid; and Dual Eligible Coverage.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE